Skip to content
Research Article Open access CC BY 4.0

AML with Additional Cytogenetic Abnormalities to t(8: 21) has Poorer Survival than that with Isolated t(8;21): A Retrospective Multicenter Cohort Study

Nahla Ahmad Bahgat Abdulateef, Manar Mohammad Ismail, Soha Aly Elmorsy, Aziza F. ALswayyed, Essam Hamed Abdou, Omima Elemam

International Blood Research & Reviews · pp. 36–46 · Published 10 Jan 2015

10.9734/IBRR/2015/15529

Abstract

Aim of the Study: To investigate the poor prognostic factors incriminated in AML with t (8; 21), particularly additional cytogenetic findings, clinicopathological presentation and their impact on survival rate in Egyptian and Saudi patients. Study Design: Patients were collected from three centers: 9 cases from King Abdullah Medical City in Makah, between 2010 and 2013, 16 from King Fahad Medical City in Riyadh, Saudi Arabia between 2007 and 2013 and 16 patients from National Cancer Institute, Cairo University, Egypt 2010 and 2013. Methodology: We studied 41 cases with t (8; 21). Immunophenotyping was performed using BD- FACS System. Conventional karyotypic analysis was done using standard culturing and banding techniques. Clinicopathological and cytogenetic data were correlated with disease outcome. Results: There was no statistically significant difference between Egyptian and Saudi patients concerning the hematological parameters or immunophenotype markers expression, Thirty four (82.9%) out of 41 patients achieved complete remission. The follow up period for the whole group ranged from 2.1 to 170.3 weeks. The median survival was 146 weeks. The overall survival rate was 80% at one year and 70% at two years. Regarding the cytogenetic profile 33/41(80.5%) had isolated t(8;21) and 8 patients (19.5%) had a chromosomal aberration in addition to t(8;21); the commonest of which was + 8 that was found  in 5 patients. The median overall survival of those 8 patients was 28.4 compared to 146.7 weeks in cases with isolated t (8; 21) p=0.002. Also, they had a lower one year overall survival rate (44%) than those with isolated t (8; 21) (86%) and their two years overall survival was zero. Conclusion: AML associated with additional cytogenetic abnormalities to t (8;21) has poorer survival than that with isolated t(8;21). Trisomy 8 is mostly incriminated for this being the most commonly encountered in this study.  

AML cytogenetic t (8; 21) FLT3 survival

References (34)

  1. 1 Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) [DOI]
  2. 2 Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia [DOI]
  3. 3 Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study [DOI]
  4. 4 Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia.
  5. 5 Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup [DOI]
  6. 6 The 8;21 translocation in leukemogenesis [DOI]
  7. 7 The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations [DOI]
  8. 8 Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. [DOI]
  9. 9 Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. [DOI]
  10. 10 Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22) [DOI]
  11. 11 Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. [DOI]
  12. 12 Prognostic Impact of Acute Myeloid Leukemia Classification: Importance of Detection of Recurring Cytogenetic Abnormalities and Multilineage Dysplasia on Survival [DOI]
  13. 13 Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.
  14. 14 Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts [DOI]
  15. 15 Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications [DOI]
  16. 16 Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome [DOI]
  17. 17 Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1‐ETO [DOI]
  18. 18 Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations [DOI]
  19. 19 Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia [DOI]
  20. 20 Acute Myeloid Leukemia Associated With Variant t(8;21) Detected by Conventional Cytogenetic and Molecular Studies [DOI]
  21. 21 Disease Features in Acute Myeloid Leukemia with t(8;21)(q22;q22). Influence of Age, Secondary Karyotype Abnormalities, CD19 Status, and Extramedullar Leukemia on Survival [DOI]
  22. 22 Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization [DOI]
  23. 23 Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21. [DOI]
  24. 24 Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis [DOI]
  25. 25 Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22) [DOI]
  26. 26 Aberrant co‐expression of CD19 and CD56 as surrogate markers of acute myeloid leukemias with t(8;21) in Taiwan [DOI]
  27. 27 Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
  28. 28 An analysis of characteristics
  29. 29 [Analysis of characteristics of 72 cases of t(8;21) acute myeloid leukemia].
  30. 30 Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution?s experience [DOI]
  31. 31 [Clinical features and prognosis of t (8; 21)/AML1-ETO-positive childhood acute myeloid leukemia].
  32. 32 [An analysis of cytogenetic characteristics and prognosis of 189 t (8; 21) acute myeloid leukemia patients].
  33. 33 [Immunophenotypic analysis of acute myeloid leukemia with t(8;21)].
  34. 34 [Clinical and experimental characteristics of 20 patients with acute myeloid leukemia with complex variant of t(8; 21)]. [DOI]

Cited by 1

Clinicopathological significance of common genetic alterations in patients with acute myeloid leukaemia 1-eight twenty-one of acute myeloid leukaemia: a retrospective cohort study

S. Nath, J. Bhattacharyya, M. Barman · The Egyptian Journal of Haematology · 2019

Related research

Article metrics

Real usage data collected on this platform.

30

Page views

0

PDF downloads

4

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.